An angiogenesis‑related lncRNA signature for the prognostic prediction of patients with bladder cancer and LINC02321 promotes bladder cancer progression via the VEGFA signaling pathway

Kang,Zhao; Dou,Qian; Huang,Ting; Tu,Maoting; Zhong,Yongping; Wang,Mei; Li,Tao

doi:10.3892/mmr.2022.12925

An angiogenesis‑related lncRNA signature for the prognostic prediction of patients with bladder cancer and LINC02321 promotes bladder cancer progression via the VEGFA signaling pathway

Authors:
- Zhao Kang
- Qian Dou
- Ting Huang
- Maoting Tu
- Yongping Zhong
- Mei Wang
- Tao Li
View Affiliations

Affiliations: Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646099, P.R. China, Department of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400011, P.R. China, Department of Respiratory Nephrology, Mianyang Fulin Hospital, Mianyang, Sichuan 621000, P.R. China, Department of Oncology, Mianyang Fulin Hospital, Mianyang, Sichuan 621000, P.R. China
Published online on: December 29, 2022 https://doi.org/10.3892/mmr.2022.12925
Article Number: 38
Copyright: © Kang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mechanism underlying bladder cancer metastasis is associated with tumor angiogenesis. The present study aimed to evaluate the predictive role and value of an angiogenesis‑associated long non‑coding (lnc)RNA signature in patients with bladder cancer and the role of long intergenic non‑coding RNA (LINC)02321 in the progression of this malignancy. Angiogenesis‑related lncRNAs were screened using Pearson correlation analysis and the signaturewas constructed using Cox regression analysis and evaluated using the receiver operating characteristic curve. LINC02321, which expressed the largest difference in bladder cancer, was screened using reverse transcription‑quantitative PCR. The role of LINC02321 in the malignant progression of bladder cancer was evaluated using Transwell, wound healing and Cell Counting Kit 8 assays. A total of six angiogenesis‑associated lncRNAs (USP30‑AS1, LINC02321, PSMB8‑AS1, KRT7‑AS, LINC01767 and OCIAD1‑AS1) were identified as candidates for the prognostic signature using Cox regression analysis. The overall survival of patients in the low‑risk group was significantly longer compared with that in the high‑risk group, with the highest area under the curve value being 0.807. A nomogram was constructed based on the traditional clinical indicators (age, sex, grade, American Joint Committee on Cancer stage) and risk score of patients. Compared with the traditional clinical indicators, the risk score demonstrated better clinical prediction capacity for predicting the prognosis of patients with bladder cancer. The Cancer Genome Atlas prediction and RT‑qPCR experimental results demonstrated that only LINC02321 was highly expressed in bladder cancer tissue and promoted the proliferation, invasion, migration and cisplatin resistance of the malignancy. Gene set enrichment, Pearson's correlation analysis and experimental results demonstrated that the VEGFA signalling pathway may be involved in the LINC02321‑regulated progression of bladder cancer. In conclusion, the six angiogenesis‑associated lncRNA signatures reported in the present study may be used to predict the prognosis of patients with bladder cancer, and LINC02321 promoted malignant progression of bladder cancer via the VEGFA signalling pathway.

View Figures

View References

1	Tran L, Xiao JF, Agarwal N, Duex JE and Theodorescu D: Advances in bladder cancer biology and therapy. Nat Rev Cancer. 21:104–121. 2021. View Article : Google Scholar : PubMed/NCBI
2	Richters A, Aben KKH and Kiemeney LALM: The global burden of urinary bladder cancer: An update. World J Urol. 38:1895–1904. 2020. View Article : Google Scholar : PubMed/NCBI
3	Patel VG, Oh WK and Galsky MD: Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 70:404–423. 2020. View Article : Google Scholar : PubMed/NCBI
4	Lenis AT, Lec PM, Chamie K and Mshs MD: Bladder cancer: A review. JAMA. 324:1980–1991. 2020. View Article : Google Scholar : PubMed/NCBI
5	Fus ŁP and Górnicka B: Role of angiogenesis in urothelial bladder carcinoma. Cent European J Urol. 69:258–263. 2016.PubMed/NCBI
6	Sonpavde G and Bellmunt J: Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma. Nat Rev Urol. 13:306–307. 2016. View Article : Google Scholar : PubMed/NCBI
7	Wigner P, Grębowski R, Bijak M, Saluk-Bijak J and Szemraj J: The interplay between oxidative stress, inflammation and angiogenesis in bladder cancer development. Int J Mol Sci. 22:44832021. View Article : Google Scholar : PubMed/NCBI
8	Zhang K, Liu D, Zhao J, Shi S, He X, Da P, You Y and You B: Nuclear exosome HMGB3 secreted by nasopharyngeal carcinoma cells promotes tumour metastasis by inducing angiogenesis. Cell Death Dis. 12:5542021. View Article : Google Scholar : PubMed/NCBI
9	Goodall GJ and Wickramasinghe VO: RNA in cancer. Nat Rev Cancer. 21:22–36. 2021. View Article : Google Scholar : PubMed/NCBI
10	Yan H and Bu P: Non-coding RNA in cancer. Essays Biochem. 65:625–639. 2021. View Article : Google Scholar : PubMed/NCBI
11	Li Y, Li G, Guo X, Yao H, Wang G and Li C: Non-coding RNA in bladder cancer. Cancer Lett. 485:38–44. 2020. View Article : Google Scholar : PubMed/NCBI
12	Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, et al: Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology. 66 (6 Suppl 1):S4–S34. 2005. View Article : Google Scholar : PubMed/NCBI
13	Wang G and McKenney JK: Urinary bladder pathology: World Health Organization classification and American joint committee on cancer staging update. Arch Pathol Lab Med. 143:571–577. 2019. View Article : Google Scholar : PubMed/NCBI
14	Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, Hernández V, Linares Espinós E, Lorch A, Neuzillet Y, et al: European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines. Eur Urol. 79:82–104. 2021. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Gao S, Yin H, Tong H, Zhan K, Yang G, Hossain MA, Li T, Gou X and He W: Nucleolar and spindle associated protein 1 (NUSAP1) promotes bladder cancer progression through the TGF-β signaling pathway. Onco Targets Ther. 13:813–825. 2020. View Article : Google Scholar : PubMed/NCBI
17	Zhan X, Jiang M, Deng W, Liu X, Chen L and Fu B: Development and validation of a prognostic nomogram for predicting cancer-specific survival in patients with lymph node positive bladder cancer: A study based on SEER database. Front Oncol. 12:7890282022. View Article : Google Scholar : PubMed/NCBI
18	Cao Z, Zhao K, Jose I, Hoogenraad NJ and Osellame LD: Biomarkers for cancer cachexia: A mini review. Int J Mol Sci. 22:45012021. View Article : Google Scholar : PubMed/NCBI
19	Patel SP and Kurzrock R: PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI
20	Wang J, Zhao X, Jiang XL, Lu D, Yuan Q and Li J: Diagnostic performance of nuclear matrix protein 22 and urine cytology for bladder cancer: A meta-analysis. Diagn Cytopathol. 50:300–312. 2022. View Article : Google Scholar : PubMed/NCBI
21	Li X, Shu K, Zhou J, Yu Q, Cui S, Liu J, Zhou R and Ding D: Preoperative plasma fibrinogen and D-dimer as prognostic biomarkers for non-muscle-invasive bladder cancer. Clin Genitourin Cancer. 18:11–19. e12020. View Article : Google Scholar : PubMed/NCBI
22	Chan TC, Hsing CH, Shiue YL, Huang SK, Hsieh KL, Kuo YH and Li CF: Angiogenesis driven by the CEBPD-hsa-miR-429-VEGFA signaling axis promotes urothelial carcinoma progression. Cells. 11:6382022. View Article : Google Scholar : PubMed/NCBI
23	Viallard C and Larrivée B: Tumor angiogenesis and vascular normalization: Alternative therapeutic targets. Angiogenesis. 20:409–426. 2017. View Article : Google Scholar : PubMed/NCBI
24	Oguntade AS, Al-Amodi F, Alrumayh A, Alobaida M and Bwalya M: Anti-angiogenesis in cancer therapeutics: The magic bullet. J Egypt Natl Canc Inst. 33:152021. View Article : Google Scholar : PubMed/NCBI
25	Hariprabu KNG, Sathya M and Vimalraj S: CRISPR/Cas9 in cancer therapy: A review with a special focus on tumor angiogenesis. Int J Biol Macromol. 192:913–930. 2021. View Article : Google Scholar : PubMed/NCBI
26	Armani G, Pozzi E, Pagani A, Porta C, Rizzo M, Cicognini D, Rovati B, Moccia F, Pedrazzoli P and Ferraris E: The heterogeneity of cancer endothelium: The relevance of angiogenesis and endothelial progenitor cells in cancer microenvironment. Microvasc Res. 138:1041892021. View Article : Google Scholar : PubMed/NCBI
27	Vallée A, Guillevin R and Vallée JN: Vasculogenesis and angiogenesis initiation under normoxic conditions through Wnt/β-catenin pathway in gliomas. Rev Neurosci. 29:71–91. 2018. View Article : Google Scholar : PubMed/NCBI
28	Schaaf MB, Houbaert D, Meçe O and Agostinis P: Autophagy in endothelial cells and tumor angiogenesis. Cell Death Differ. 26:665–679. 2019. View Article : Google Scholar : PubMed/NCBI
29	Chen C, Luo Y, He W, Zhao Y, Kong Y, Liu H, Zhong G, Li Y, Li J, Huang J, et al: Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J Clin Invest. 130:404–421. 2020. View Article : Google Scholar : PubMed/NCBI
30	Zheng R, Du M, Wang X, Xu W, Liang J, Wang W, Lv Q, Qin C, Chu H, Wang M, et al: Exosome-transmitted long non-coding RNA PTENP1 suppresses bladder cancer progression. Mol Cancer. 17:1432018. View Article : Google Scholar : PubMed/NCBI
31	Li X, Zhang C, Peng X, Li Y, Chen G, Gou X, Zhou X and Ma C: A novel risk score model based on five angiogenesis-related long non-coding RNAs for bladder urothelial carcinoma. Cancer Cell Int. 22:1572022. View Article : Google Scholar : PubMed/NCBI
32	Tong H, Li T, Gao S, Yin H, Cao H and He W: An epithelial-mesenchymal transition-related long noncoding RNA signature correlates with the prognosis and progression in patients with bladder cancer. Biosci Rep. 41:BSR202039442021. View Article : Google Scholar : PubMed/NCBI
33	Qing L, Gu P, Liu M, Shen J, Liu X, Guang R, Ke K, Huang Z, Lee W and Zhao H: Extracellular matrix-related six-lncRNA signature as a novel prognostic biomarker for bladder cancer. Onco Targets Ther. 13:12521–12538. 2020. View Article : Google Scholar : PubMed/NCBI
34	Claesson-Welsh L and Welsh M: VEGFA and tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar : PubMed/NCBI
35	Zhao J, Du P, Cui P, Qin Y, Hu C, Wu J, Zhou Z, Zhang W, Qin L and Huang G: LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. Oncogene. 37:4094–4109. 2018. View Article : Google Scholar : PubMed/NCBI
36	Hu R, Bi R, Jiang L, Yang X, Zhong Y and Xie X: LncRNA TUSC8 suppresses the proliferation and migration of esophageal cancer cells by downregulation of VEGFA. J Cancer. 12:6393–6400. 2021. View Article : Google Scholar : PubMed/NCBI
37	Guo H, Li J, Fan F and Zhou P: LINC00707 regulates miR-382-5p/VEGFA pathway to enhance cervical cancer progression. J Immunol Res. 2021:55246322021. View Article : Google Scholar : PubMed/NCBI
38	Chen L, Qiu CH, Chen Y, Wang Y, Zhao JJ and Zhang M: LncRNA SNHG16 drives proliferation, migration, and invasion of lung cancer cell through modulation of miR-520/VEGF axis. Eur Rev Med Pharmacol Sci. 24:9522–9531. 2020.PubMed/NCBI
39	Cao W, Zhao Y, Wang L and Huang X: Circ0001429 regulates progression of bladder cancer through binding miR-205-5p and promoting VEGFA expression. Cancer Biomark. 25:101–113. 2019. View Article : Google Scholar : PubMed/NCBI
40	Wang H, Niu X, Jiang H, Mao F, Zhong B, Jiang X and Fu G: Long non-coding RNA DLX6-AS1 facilitates bladder cancer progression through modulating miR-195-5p/VEGFA signaling pathway. Aging (Albany NY). 12:16021–16034. 2020. View Article : Google Scholar : PubMed/NCBI